Synlogic

Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., June 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of the investigational Synthetic Biotic medicine™ SYNB8802 for the treatment of Enteric Hyperoxaluria and on SYNB1934, an evolved strain of Synthetic Biotic medicine SYNB1618, for the treatment of Phenylketonuria (PKU) during the Synthetic Biology: Engineering, Evolution & Design (SEED) conference, being held virtually June 15-18, 2021.

Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

CAMBRIDGE, Mass., June 3, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on June 10, 2021 at 9:00 am ET.

Synlogic Reminds Stockholders of 2021 Annual General Meeting Details

CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B.

Synlogic to Present at Upcoming Virtual Banking and Industry Conference

CAMBRIDGE, Mass., May 23, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on an investigational program to develop Synthetic Biotic™ medicines for the treatment of  inflammatory bowel disease (IBD) during Digestive Disease Week (DDW), being held virtually May 21-23, 2021.

Synlogic Presents Data at Digestive Disease Week (DDW) on a Novel Approach for the Treatment of Inflammatory Bowel Disease

Synlogic, Inc. (SYBX) CEO Dr. Aoife Brennan on Q1 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., May 13, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the first quarter ended March 31, 2021, and provided an update on its clinical and preclinical programs.

Synlogic Reports First Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass., May 6, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its first quarter 2021 financial results before the market opens on Thursday, May 13, 2021.

Synlogic Announces First Quarter 2021 Conference Call & Webcast

Abeona Therapeutics

Fortress Biotech

Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.

3 Penny Stocks That Wall Street Wants You To Buy Now

CTI BioPharma

Energy Focus

ION Geophysical

Pixelworks

Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.

7 Penny Stocks That May Not Be Penny Stocks For Long

Evogene

PAVmed

Savara

Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy According To Analysts With Price Targets Up to 341%

CAMBRIDGE, Mass., April 13, 2021 Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data from the Phase 1 study of SYNB1618 for the treatment of Phenylketonuria (PKU) during the American College of Medical Genetics (ACMG) annual meeting, being held virtually April 13-16, 2021.

Synlogic Presents Data Demonstrating Activity of a Solid Oral Formulation of SYNB1618 at American College of Medical Genetics (ACMG) Annual Meeting

CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on SYNB1891 for the treatment of solid tumors and lymphoma during the American Association for Cancer Research (AACR) annual meeting, April 10-15, 2021.

Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B.

Synlogic to Present at Upcoming Virtual Banking and Industry Conferences

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass., March 25, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the fourth quarter and full year ended December 31, 2020, and provided an update on programs and progress.

Synlogic Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low calcium diet were treated with multiple ascending doses of SYNB8802.

Synlogic Announces SYNB8802 Will Advance to Phase 1B Proof of Concept Study After Proof of Mechanism Demonstrated in Dietary Hyperoxaluria

CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its fourth quarter and full year 2020 financial results before the market opens on Thursday, March 25, 2021.

Synlogic Announces Fourth Quarter and Full Year 2020 Conference Call & Webcast

CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- A collaboration between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, has been recognized by the Air Force Research Laboratory (AFRL) as a...

Joint Team from MIT and Synlogic Named a Biotechnology Grand Challenge Winner by Air Force Research Laboratory

Investors need to pay close attention to Synlogic (SYBX) stock based on the movements in the options market lately.

Do Options Traders Know Something About Synlogic (SYBX) Stock We Don't?

CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined significant clinical milestones for 2021 and provided an overview of recent progress. "With three...

Synlogic Outlines Upcoming Clinical Milestones

AnPac Bio-Medical Science Co

Aerpio Pharmaceuticals Inc

Arvinas Inc

Veru

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific updates. Arvinas Inc (NASDAQ: ARVN): The smid-cap biopharma announced clinical program updates for its protein degraders ARV-471 and ARV-110.

5 Biopharma Stocks Making Big Moves Monday

CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. SYNB1891...

Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma

CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Michael Heffernan to its board of directors. "We are delighted to welcome Mike...

Synlogic Appoints Michael Heffernan to its Board of Directors

CAMBRIDGE, Mass., Dec. 7, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present additional translational and in silico data on SYNB8802, a Synthetic Biotic...

Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome Engineering

Synlogic (SYBX) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.

News for Synlogic Stock (SYBX)